Natalizumab and progressive multifocal leucoencephalopathy.
Current data suggest that as many as 1 in 1000 treated individuals may develop progressive multifocal leucoencephalopathy (PML) in concert with the use of natalizumab. Natalizumab was withdrawn in early 2005. The present paper provides a comprehensive description of PML and reviews the role of natalizumab in the pathogenesis of PML. It is likely that use of drugs which cause specific perturbations of the immune system will be accompanied by similar rare infections. Thus researchers should be on the alert when using such agents in clinical trials.
Berger
J R
JR
Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, 740 S Limestone Street, Lexington, KY 40536-0284, USA. jrbneuro@uky.edu.
D017088:AIDS-Related Opportunistic Infections / Q000139:chemically induced / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy; D000069442:Natalizumab; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D011379:Prognosis
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab